News & Updates
Filter by Specialty:
HK data: SGLT2 inhibitors cut risks of respiratory and renal diseases in T2DM
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risks of respiratory and renal diseases vs dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM), researchers from the University of Hong Kong (HKU) have reported.
HK data: SGLT2 inhibitors cut risks of respiratory and renal diseases in T2DM
29 Mar 2023
How to differentiate COVID-19 pneumonia from influenza and bacterial pneumonia on CT?
Arched bridge and/or vacuole signs on CT may support a diagnosis of COVID-19 pneumonia and assist in differentiation from influenza and bacterial pneumonia, a retrospective study by the Chinese University of Hong Kong has revealed.
How to differentiate COVID-19 pneumonia from influenza and bacterial pneumonia on CT?
28 Mar 2023
COVID-19 vaccine risk-benefit ratio favourable for patients with rheumatic diseases
In the CONVIN-SING* study, there was a favourable risk-benefit ratio for COVID-19 vaccination in individuals with autoimmune inflammatory rheumatic diseases (AIIRD) who have received a COVID-19 mRNA vaccine.
COVID-19 vaccine risk-benefit ratio favourable for patients with rheumatic diseases
28 Mar 2023
Hands-free, pocket-size device helps ease breathing for people with COPD
A small positive-expiratory pressure (PEP) device that can be used on-demand shows promise for improving the lives of people with chronic obstructive pulmonary disease (COPD), according to a study.
Hands-free, pocket-size device helps ease breathing for people with COPD
27 Mar 2023
Long-term dupilumab proven safe, effective in children with asthma
Long-term treatment with dupilumab is well tolerated, and its efficacy in children with uncontrolled, moderate-to-severe asthma as seen in the VOYAGE study is consistent, according to the EXCURSION open-label extension study. In addition, patients who switched from placebo to dupilumab has improved rapid lung function.
Long-term dupilumab proven safe, effective in children with asthma
24 Mar 2023
Triple combination asthma inhaler works in patients with persistent airflow limitation
A novel once-a-day inhaler for asthma that contains a fixed-dose combination of the corticosteroid mometasone furoate (MF), the long-acting beta-agonist indacaterol acetate (IND), and the long-acting muscarinic antagonist glycopyrronium bromide (GLY) appears to have a favourable effect in patients with persistent airflow limitation (PAL), according to a post hoc analysis of the IRIDIUM study.